UCB (OTCMKTS:UCBJY) Share Price Crosses Above 50 Day Moving Average – Should You Sell?

UCB SA (OTCMKTS:UCBJY)’s share price crossed above its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $137.71 and traded as high as $141.49. UCB shares last traded at $141.1670, with a volume of 32,273 shares.

Wall Street Analysts Forecast Growth

Several brokerages have commented on UCBJY. Zacks Research downgraded shares of UCB from a “strong-buy” rating to a “hold” rating in a report on Monday, November 3rd. Jefferies Financial Group upgraded shares of UCB to a “moderate sell” rating in a report on Sunday, October 26th. One research analyst has rated the stock with a Strong Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy”.

UCB Stock Performance

The stock has a 50 day moving average price of $137.71 and a 200 day moving average price of $120.40.

About UCB

UCB is a global biopharmaceutical company founded in Belgium in 1928, specializing in the discovery and development of therapies for severe diseases in the fields of neurology and immunology. Headquartered in Brussels, UCB leverages nearly a century of scientific expertise to address areas of high unmet medical need, with a focus on chronic conditions such as epilepsy, Parkinson’s disease, rheumatoid arthritis and Crohn’s disease.

The company’s commercial portfolio includes key branded medicines such as CIMZIA (certolizumab pegol) for inflammatory disorders, VIMPAT (lacosamide) for the treatment of partial-onset seizures in epilepsy, and NEUPRO (rotigotine transdermal system) for Parkinson’s disease and restless legs syndrome.